Pfizer Halts Trial Over Safety Concerns
Pfizer has been asked by the FDA to suspend chronic pain studies involving tanezumab because of safety concerns.
Pfizer has been asked by the FDA to suspend chronic pain studies involving tanezumab because of safety concerns. The investigational compound had been touted by some as a potential blockbuster.
Tanezumab’s problems began last month when an osteoarthritis clinical trial was halted following reports that some patients’ osteoarthritis had worsened, necessitating joint replacement. In its press statement, Pfizer claimed that the adverse event had not been observed in non-osteoarthritis patient populations.
However, the FDA has further considered the reports and is concerned that there is potential for such events to occur in other patient populations in which the compound is being studied. As such, Pfizer has suspended its tanezumab studies for chronic low back pain and painful diabetic peripheral neuropathy, although it will continue investigation of the compound in some areas of high unmet medical need, such as cancer pain.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
